Regeneron Shares Fall After Q1 Earnings Beat and New Repurchase Program
Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 5.5% despite reporting better-than-expected Q1 results and announcing a $3 billion share repurchase program. Revenue and earnings exceeded forecasts, but concerns over margin pressures and declining sales of Eylea's standard version weighed on investor sentiment.
Topics: Earnings Margin Decline Product Sales Revenue Growth Share Repurchase Stock Price Movement